These CAR-Ts have a surface receptor that works like an antigen recognition domain, which recognizes surface receptor targets such as CD19, leading to activation, cytokine secretion, and cellular proliferation, which in turn lead to tumor eradication. The gene discussed is CD19; the disease is neoplasm.